China Batten’s Disease (CLN-2) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Batten disease, also known as neuronal ceroid lipofuscinosis, refers to a group of rare inherited neurological conditions that can cause vision loss, progressive motor and cognitive decline, and seizures. The global prevalence of the Batten’s disease is estimated to be 1 to 2 of every 100,000 persons. Juvenile Batten disease occurs in children between ages five and 10. These patients usually live until their late teens or early 20s.
China is a growing market for batten’s disease (CLN-2) due to increase in research and development, introduction of novel disease therapies, rise in demand for effective therapies among patients and upsurge in global prevalence (1-2 per 100,000 persons) of the disease are projected to fuel the growth of the batten disease market during the forecast period.
However, there are some restraining factors for growth of battens disease therapeutics market in China such as overall high cost of treatment and lack of novel treatment methods.